Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
The publication presents a Phase II clinical trial evaluating the efficacy and safety of a novel targeted therapy in patients with advanced non-small cell lung cancer harboring specific genetic mutations.
Results demonstrated:
- Significant improvement in progression-free survival compared to standard treatments
- Manageable safety profile
These findings support further development and potential incorporation of this targeted agent in personalized treatment strategies for this patient population.